Chimeric bacteriophage lysin with activity against staphylococci bacteria
AssigneeThe Rockefeller University
InventorsVincent A. Fischetti, Anu Daniel, Chad Euler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
Claims23
A chimeric bacteriophage lysin comprising a catalytic domain of a first Staphylococcus-specific phage lysin and a binding domain of a second Staphylococcus-specific phage lysin, wherein the chimeric lysin has killing activity against Staphylococcus aureus.
(canceled)
(canceled)
A method of detecting the presence of a staphylococcal bacteria comprising the step of contacting a peptide comprising the amino acid sequence of SEQ ID NO:1 that specifically binds to staphylococcal bacteria, or comprising a variant of SEQ ID NO:
- 1 wherein the variant specifically binds to staphylococcal bacteria, with a sample, and detecting the peptide within the sample.
(canceled)
Dependencies are inferred from the claim text.